AMVUTTRA™ (vutrisiran) may halt the progression of or reverse the polyneuropathy of hATTR amyloidosis with dosing once every 3 months1,2

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.1 At 9 months in a randomized, open-label study, patients treated with AMVUTTRA were compared with an external placebo group and demonstrated:

  • Improvement in neuropathy impairment, as measured by mNIS+71
  • Improvement in quality of life, as measured by Norfolk QoL-DN1
  • Improvement in gait speed, as measured by 10MWT1

mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy; 10MWT=10-meter walk test.

Learn about the clinical profile for AMVUTTRA
AMVUTTRA™ (vutrisiran) clinical profile

Explore the pivotal study design, efficacy, and safety of AMVUTTRA.

Download brochure

How to get your patients started with AMVUTTRA

Electronic Start Form
Computer icon

Complete and submit the Electronic Start Form online with your patient

Electronic Start Form
DocuSign Start Form
Pen and paper icon

Begin the Start Form and send to your patient over email to complete via DocuSign

DocuSign Start Form
Downloadable Start Form
Printer icon

Print, complete with your patient, and fax the Start Form to 1-833-256-2747

Start Form

Patient support through Alnylam Assist™

Alnylam Assist offers a range of support to guide your patients through treatment with AMVUTTRA including:

Piggy bank icon

Financial assistance programs for eligible patients.a
These may include:

  • Alnylam Assist Patient Assistance Program (PAP): Provides AMVUTTRA at no cost to eligible patients, primarily the uninsured, who meet specific financial criteria
  • Alnylam Assist Commercial Copay Programb: Covers certain out-of-pocket costs for eligible patients with commercial insurance
Man with chart icon

AMVUTTRA coverage, coding, and reimbursement education and patient-specific benefit verification

Pen and paper icon

Help with ordering AMVUTTRA via specialty distributor or specialty pharmacy

a Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

b Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist Commercial Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

8 AM–6 PM ET, Monday–Friday
Phone icon 1-833-256-2748
Printer icon 1-833-256-2747
To learn more, visit www.AlnylamAssist.com

Subscribe to

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA™ (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Adams D, Tournev I, Taylor M, et al. Slides presented at la Société Francophone du Nerf Périphérique (SFNP); January 21-22, 2022.

Important Safety Information and Indication

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA™ (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

For additional information about AMVUTTRA, please see the full Prescribing Information.

For patients

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA™ (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.